Tempest Therapeutics Schedules Shareholder Vote for F-star Merger
Ticker: TPST · Form: 8-K · Filed: Jun 14, 2024 · CIK: 1544227
| Field | Detail |
|---|---|
| Company | Tempest Therapeutics, Inc. (TPST) |
| Form Type | 8-K |
| Filed Date | Jun 14, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: merger, shareholder-meeting, business-combination
TL;DR
Tempest shareholders vote July 15 on F-star merger; deal expected Q3.
AI Summary
On June 13, 2024, Tempest Therapeutics, Inc. filed an 8-K report detailing a special meeting of stockholders scheduled for July 15, 2024. The primary purpose of this meeting is to vote on a proposed business combination with F-star Therapeutics Limited. This transaction is expected to close in the third quarter of 2024.
Why It Matters
This filing signals a significant step towards the completion of Tempest's merger with F-star, which could reshape the company's strategic direction and pipeline.
Risk Assessment
Risk Level: medium — The success of the merger is subject to shareholder approval and closing conditions, introducing execution risk.
Key Players & Entities
- Tempest Therapeutics, Inc. (company) — Registrant
- F-star Therapeutics Limited (company) — Proposed business combination partner
- July 15, 2024 (date) — Date of special meeting of stockholders
- Third quarter of 2024 (date) — Expected closing period for the business combination
FAQ
What is the primary purpose of the special meeting of stockholders?
The primary purpose is to vote on a proposed business combination with F-star Therapeutics Limited.
When is the special meeting of stockholders scheduled to take place?
The special meeting is scheduled for July 15, 2024.
Who is Tempest Therapeutics, Inc. proposing to combine with?
Tempest Therapeutics, Inc. is proposing to combine with F-star Therapeutics Limited.
When is the business combination expected to close?
The business combination is expected to close in the third quarter of 2024.
What is the exact date of the report?
The date of the report is June 13, 2024.
Filing Stats: 639 words · 3 min read · ~2 pages · Grade level 12.1 · Accepted 2024-06-14 16:41:58
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share TPST The Nasdaq Stock Mar
Filing Documents
- d853541d8k.htm (8-K) — 33KB
- 0001193125-24-161685.txt ( ) — 188KB
- tpst-20240613.xsd (EX-101.SCH) — 4KB
- tpst-20240613_def.xml (EX-101.DEF) — 13KB
- tpst-20240613_lab.xml (EX-101.LAB) — 22KB
- tpst-20240613_pre.xml (EX-101.PRE) — 14KB
- d853541d8k_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TEMPEST THERAPEUTICS, INC. Date: June 14, 2024 By: /s/ Stephen Brady Name: Stephen Brady Title: Chief Executive Officer